On March 6, 2006 Synosia Therapeutics completed their series A funding round with $2.5 million in capital from undisclosed investors.
On January 1, 2009 Synosia Therapeutics completed their series B funding round with $29 million in funding from Investor Growth Capital Limited (lead investor), Aravis Ventures (lead investor), Versant Ventures, Swiss Helvetia Fund, Novo Ventures, Abingworth, and 5AM Ventures.
On October 12, 2010 Synosia Therapeutics completed their series C funding round with $30 million in funding from UCB Pharma (lead investor), Versant Ventures, Swiss Halvetia Fund, Novo Holdings, Investor Growth Capital Limited, Aravis Ventures, and 5AM Ventures.
Synosia Therapeutics raises a $30,000,000 series C round from Swiss Helvetia, Versant Ventures, Aravis Ventures, 5AM Ventures and Patricia Industries.
Synosia Therapeutics raises a $29,000,000 series B round from Swiss Helvetia, Abingworth, Versant Ventures, Aravis Ventures, 5AM Ventures, Patricia Industries and Novo Ventures.
Synosia Therapeutics was founded.
BioTie Therapies Corp. to Acquire CNS Therapeutics Firm Synosia Therapeutics in $121.5M All-Shares Deal
Synosia Therapeutics Raises $30M in Series C Financing
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.